Cereno Scientific B CRNO B
This picture changes. Follow Cereno Scientific B free — email when the signal or risk changes + a Sunday weekly brief.
Follow Cereno Scientific B freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Full analysis: 22 Jul 2026
Latest news check: 6 Aug 2026
General analysis — not personal advice.
HOLD
6/10
Confidence
A smaller speculative position may be justified for risk-tolerant investors ahead of upcoming catalysts.
Promising pipeline and recently secured financing are balanced by high execution risk and ongoing capital needs, supporting a neutral stance.
Market sentiment
7/10
↑
Trend: Improving
The market reacts positively to insider purchases and study progress despite weak share price performance.
Price context
The stock trades near its 52-week low at 4.764 SEK, about 53% below its peak, indicating the market is awaiting clear pipeline progress.
Risk assessment
7/10
Dilution:
Medium
Capital need within 12-24 months
Jurisdiction:
Low
Operations in Sweden and USA
Execution:
High
Early-stage clinical trials with history of delays
Cash flow:
6 mo
Recent changes
- ▼ Execution risk is raised from medium to high driven by a track record of delays in early-stage clinical studies.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (10) — follow the company freeAbout the company
Cereno Scientific develops epigenetic drug candidates for rare cardiopulmonary diseases. The company is in the clinical stage with focus on PAH and PH-ILD and has no product revenues.
Sector:
Biotech / Drug development
Type:
Biotech
Next report
26 Aug 2026
Q2
Catalysts
Q3 2026
CS1 Phase IIb start
High
Q3 2026
CS014 PK results
High
Q4 2026
Partnership agreement
Medium
Horizon:
Bull case
Positive safety data and insider purchases strengthen confidence ahead of the Phase IIb studies.
Bear case
High burn rate and need for continued financing create dilution risk.
Signal rationale (informational)
Promising pipeline and recently secured financing are balanced by high execution risk and ongoing capital needs, supporting a neutral stance.
Recent news
- No new press releases or company-specific events after 22 July 2026. CEO insider purchase published 22 July confirms prior information.
Key figures
Revenue TTM
TTM
SEK 0.0M
EBITDA
Q1 2026
SEK -28.6M
Net income
Q1 2026
SEK -28.6M
Cash
Q1 2026
SEK 71.0M
Shares outstanding
Q2 2026
324M
EPS
Q1 2026
SEK -0.09
Price & valuation
Last close
SEK 4.74
Market Cap
SEK 1.5B
1 week
-0.5 %
3 months
-13.9 %
12 months
-47.9 %
From 52w high
-53.5 %
From 52w low
+7.7 %
Exchange
First North
Type
Biotech
Sector
Biotech / Drug development
This picture changes. Follow Cereno Scientific B free — email when the signal or risk changes + a Sunday weekly brief.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.